Key result
Regression of left ventricular hypertrophy using captopril or TCV-116 reduced the incidence of ischemia-induced VT/Vf to 0% and 10%, respectively, compared to 63% in untreated hypertensive rats.
Why the study?
Does regression of left ventricular hypertrophy by antihypertensive treatment prevent ischemia-induced lethal arrhythmias in spontaneously hypertensive rats?
Does regression of left ventricular hypertrophy by antihypertensive treatment prevent ischemia-induced lethal arrhythmias in spontaneously hypertensive rats?
Absolute Event Rate: 0% vs 63%
Regression of left ventricular hypertrophy by angiotensin II blockade reduces electrical inhomogeneity and prevents ischemia-induced lethal arrhythmias in a rat model.
No takes yet. Share an insight, caveat, or question.
LVH regression may prevent ischemia-induced VT/VF in hypertensive rat models; leaves open clinical translation to patients.
Kohya et al. (1995) studied Left ventricular hypertrophy. Captopril, TCV-116, or hydralazine vs. Untreated SHR and WKY rats was evaluated on Incidence of ventricular tachycardia or ventricular fibrillation (VT/Vf) after left coronary artery occlusion. Regression of left ventricular hypertrophy using captopril or TCV-116 reduced the incidence of ischemia-induced VT/Vf to 0% and 10%, respectively, compared to 63% in untreated hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: